52
Participants
Start Date
October 31, 2015
Primary Completion Date
February 28, 2018
Study Completion Date
July 31, 2018
PRO 140
PRO 140 is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
Placebo
Optimized Background Regimen
Optimized background therapy (OBT) is chosen on the basis of a subject's resistance test results and treatment history.
CD02 Investigational site, New York
CD02 Investigational site, New York
CD02 Investigational site, Syracuse
CD02 Investigational Site, Washington D.C.
CD02 Investigational site, Washington D.C.
CD02 Investigational site, Miami
CD02 Investigational Site, Annandale
CD02 Investigational site, Charlotte
CD02 Investigational site, Orlando
CD02 Investigational site, Miami
CD02 Investigational site, Miami Beach
CD02 Investigational Site, Miami
CD02 Investigational site, West Palm Beach
CD02 Investigational Site, Clearwater
CD02 Investigational site, Ft. Pierce
CD02 Investigational site, Cincinnati
CD02 Investigational site, Chicago
CD02 Investigational site, Wichita
CD02 Investigational site, Dallas
CD02 Investigational Site, Houston
CD02 Investigational site, Houston
CD02 Investigational Site, Bellaire
CD02 Investigational Site, Austin
E Study Site, Las Vegas
CD02 Investigational site, Los Angeles
CD02 Investigational Site, Los Angeles
CD02 Investigational site, Long Beach
CD02 Investigational site, Palm Springs
CD02 Investigational site, Fountain Valley
CD02 Investigational Site, San Francisco
CD02 Investigational site, San Francisco
CD02 Investigational Site, Spokane
CD02 Investigational Site, New Haven
CD02 Investigational site, Norwalk
CD02 Investigational site, Ponce
CD02 Investigational site, San Juan
Lead Sponsor
CytoDyn, Inc.
INDUSTRY